Skip to main content

Advertisement

SpringerLink
Log in

Prevention

Will an aspirin a day keep the colorectal cancer away?

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

A long-term follow-up study that assessed the effect of daily aspirin on colorectal cancer incidence concluded that it significantly reduced the risk of colon cancer, but not rectal cancer. Detailed analysis of the findings indicate that it is too soon to recommend daily aspirin for cancer prevention in healthy individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chan, A. T., Ogino, S. & Fuchs, C. S. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356, 2131–2142 (2007).

    Article  CAS  PubMed  Google Scholar 

  2. Gao, F. et al. The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials. Colorectal Dis. 11, 893–901 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).

    Article  CAS  PubMed  Google Scholar 

  4. Benamouzig, R. & Uzzan, B. Aspirin to prevent colorectal cancer: time to act? Lancet 376, 1713–1714 (2010).

    Article  PubMed  Google Scholar 

  5. Markowitz, S. D. & Bertagnolli, M. M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449–2460 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yan, M. et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl Acad. Sci. USA 106, 9409–9413 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cross, J. T., Poole, E. M. & Ulrich, C. M. A review of gene-drug interactions for non-steroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J. 8, 237–247 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Benamouzig, R. et al. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut 59, 622–629 (2010).

    Article  CAS  PubMed  Google Scholar 

  9. Midgley, R. S. et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J. Clin. Oncol. 28, 4575–4580 (2010).

    Article  CAS  PubMed  Google Scholar 

  10. Kirkegaard, H. et al. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ 341, c5504 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Stavanger University Hospital, Armauer Hansens vei 20, POB 8100, N-4068, Stavanger, Norway

    Marianne Berg & Kjetil Søreide

Authors
  1. Marianne Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kjetil Søreide
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kjetil Søreide.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, M., Søreide, K. Will an aspirin a day keep the colorectal cancer away?. Nat Rev Clin Oncol 8, 130–131 (2011). https://doi.org/10.1038/nrclinonc.2010.225

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.225

  • Springer Nature Limited

Search

Navigation